Navigation Links
NxStage Says 'Thank You' to Patients and Care Partners at the 2nd Annual NxStageUsers Meet-Up and Conference in New Orleans
Date:10/5/2011

in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements including market acceptance and demand for NxStage's System One, growth in home hemodialysis, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including Quarterly Report on Form 10Q for the quarter ended June 30, 2011.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.

Media Contacts:

Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
ir@nxstage.com
978-332-5923


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NxStage System One Patients Join Patient Advocacy Groups on Capitol Hill
2. NxStage Board Member Dr. Barry M. Straube Honored with Prestigious Award from the American Association of Kidney Patients
3. NxStage: NIH Study Published in New England Journal of Medicine Adds to Growing Body of Evidence in Support of More Frequent Hemodialysis
4. NxStage to Present at UBS Global Life Sciences Conference
5. NxStage Medical Founder and CEO Jeffrey Burbank Honored With Mass High Tech All-Star Award
6. Former NxStage System One User Celebrates One-Year Kidney Transplant Anniversary
7. NxStage® Highlights Non-Medical Emergency Preparedness Guidebook for System One™ Home Hemodialysis Patients
8. NxStage Celebrates Seven Year Anniversary of IU Healths Home Hemodialysis Program and Patient Milestones
9. NxStage Announces Third Quarter 2011 Investor Conference Schedule
10. NxStage Reports Record Second Quarter 2011 Financial Results and Raises Revenue Guidance for 2011
11. NxStage® Enters Into New Lease for Corporate Headquarters Within Lawrence, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , July 23, 2014 Inovio ... successful results from its randomized, double-blind, placebo-controlled ... with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) ... or 18. Treatment with VGX-3100, Inovio,s HPV16/18-specific ... to CIN1 or no disease, meeting the ...
(Date:7/23/2014)... , July 23, 2014  The management ... CBRX ) will hold a conference call on ... the second quarter ended June 30, 2014.  The ... 31, 2014Time: , 8:30 am EDTDial-in numbers: , ... or,International: (412) 317-0790Webcast (live & archive): , ...
(Date:7/23/2014)... Global healthcare company GSK reports Q2 results ... price competition and supply disruptions to its Consumer business. ... out that the company is very much in transition, citing ... about long-term prospects as well as the investments being ... Simon Dingemans adds that the company is reining ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2
(Date:7/23/2014)... The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... at the UPMC/UPCI Multidisciplinary Thyroid Center and other ... getting the correct initial surgery by 30 percent, ...
(Date:7/23/2014)... FL (PRWEB) July 23, 2014 Men ... pay higher premiums for life insurance based on national ... cheap life insurance rates search to its comprehensive tool ... at http://quotespros.com/life-insurance.html . , Providers that are ... selected, sorted and reviewed in one or two clicks. ...
(Date:7/23/2014)... near Sellafield or Dounreay since the 1990s are not ... research published in the British Journal of Cancer ... Research Group at the University of Oxford and from ... among those who were under 25 and living near ... in cancer incidence from 1991-2006 between those living near ...
(Date:7/23/2014)... New York, New York (PRWEB) July 23, 2014 ... that the use of a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ... uterine sarcoma and other cancers throughout a woman’s body, ... on July 22nd in the Journal of the American ... hysterectomy using a power morcellator at 500 U.S. hospitals ...
(Date:7/23/2014)... Asking patients if a suspicious skin lesion is ... spot is likely to be cancerous, according to a ... the Department of Dermatology at Temple University School of ... Dermatology on July 23, 2014, found that nearly ... by itching, while 28.2 percent involve pain. Non-melanoma skin ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
... ... with blogs, groups, forums, photos and videos , ... Norfolk, Va. (PRWEB) November 2, 2009 -- HealthCareerWeb.com, a full service healthcare ... online health care jobs section with its medical professional network . , ...
... 2 STANDUP FOR KIDS has been chosen by STAR ... businesses are being asked to join forces for charity ... for November,s National Homeless Youth Awareness Month. Local business ... OF THE NEIGHBORHOOD, are displaying posters and encouraging their customers ...
... On Thursday, November 5, 2009, at 8:30 a.m. Eastern/2:30 p.m. ... (Nasdaq and MTA: CTIC) management team will host a conference ... , , Conference Call Numbers, ... p.m. Central European/5:30 a.m. Pacific Time, 1-877-941-6010 ...
... , the journal of the American Academy of Ophthalmology ... surgery is likely to benefit patients with age-related macular ... a clinical trial showing that the steroid triamcinolone may ... when standard treatment fails, and on the public,s use ...
... Nov. 1 Schering-Plough Corporation (NYSE: SGP ) ... with boceprevir combination therapy in patients with chronic hepatitis ... were presented at the American Association for the Study ... 30-Nov. 3. , Boceprevir is an investigational ...
... body fat means greater survival odds, researcher says , SUNDAY, Nov. ... are much more likely to die than other people on dialysis, ... study has found. , Researchers measured body fat percentage in 671 ... rate for people with less than 10 percent body fat was ...
Cached Medicine News:Health News:HealthCareerWeb.com is Redesigned to Integrate Healthcare Job Board with Medical Professional Network 2Health News:HealthCareerWeb.com is Redesigned to Integrate Healthcare Job Board with Medical Professional Network 3Health News:Local Businesses Unite, Calling an End to Youth Homelessness 2Health News:Cataract surgery helps AMD patients; steroid improves DME; online eye health forum 2Health News:Cataract surgery helps AMD patients; steroid improves DME; online eye health forum 3Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 3Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 4Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 5Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 6Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 7Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 8Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 9Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 10Health News:Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting 11
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... Digital Pulse Oximeter monitors SpO2, ... It is designed to provide ... patients. The device rejects spontaneous ... the operator of excess artifacts ...
... The 8600FO is designed to ... MRI users for patient safety ... Fiber Optic Sensors and Cables ... is eliminated, as well as ...
... The 8600 Series Tabletop/Portable ... simple universal tool for patient ... continuous monitoring, the 8600 has ... professionals worldwide and is recognized ...
Medicine Products: